Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes

ABT-770 [( S)- N-[1-[[4′-trifluoromethoxy-[1,1′-biphenyl]-4-yl]oxy]methyl-2-(4,4-dimethyl-2,5-dioxo-1-imidazolidinyl)ethyl]- N-hydroxyformamide], a matrix metalloproteinase inhibitor (MMPI), produced generalized phospholipidosis in rats. Phospholipid accumulation was accompanied by retention of drug...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biochemical pharmacology 2001-12, Vol.62 (12), p.1661-1673
Hauptverfasser:	Gum, Rebecca J., Hickman, Dean, Fagerland, Jane A., Heindel, Matthew A., Gagne, Gerard D., Schmidt, James M., Michaelides, Michael R., Davidsen, Steven K., Ulrich, Roger G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Biological and medical sciences Biphenyl Compounds - adverse effects Biphenyl Compounds - metabolism Errors of metabolism Formamides - metabolism Formamides - pharmacology Hepatocytes Hepatocytes - drug effects Hepatocytes - metabolism HIV Protease Inhibitors - adverse effects HIV Protease Inhibitors - metabolism Human Humans Hydroxamic Acids - adverse effects Hydroxamic Acids - metabolism Lipidoses - chemically induced Lipids (lysosomal enzyme disorders, storage diseases) Male Matrix metalloproteinase (MMP) Matrix Metalloproteinase Inhibitors Matrix Metalloproteinases - metabolism Medical sciences Metabolic diseases Metabolism Phospholipidosis Rat Rats Rats, Sprague-Dawley
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!